Wellcome Trust joins $40m series-B for Kymab

The funds will enable the company to invest further in its Kymouse human monoclonal antibody technology. Kymab will also seek to enter into various strategic research and development collaborations following the deal.

Wellcome Trust provided $20m of funding in the round.

Following the investment, Kymab will work alongside the Gates Foundation on vaccine antigen discovery, with an initial focus on malaria and HIV.

In 2010, shortly after Kymab was set up, Wellcome Trust provided £20m of series-A funding to the company to further advance technology developed at The Sanger Institute. The venture investor recently joined a €30m series-E round for Swiss molecular diagnostics firm Biocartis.

Company
Founded in 2009, Kymab is a biopharmaceutical company that develops technology for the discovery and development of therapeutic monoclonal antibodies. The company employs a team of 50 and is headquartered in Cambridge.

People
Sir William Castell is chairman and Jeremy Farrar is the director of the Wellcome Trust. Dr Christian Grøndahl is CEO of Kymab.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Healthcare
• Early-stage
• United Kingdom